Andrew Chadeayne

The U.S. Food and Drug Administration (FDA) has offered positive feedback to CaaMTech, Inc. on its CT-4201 psilocin prodrug program, specifically endorsing the company's approach to addressing "functional unblinding" in its drug trials. This regulatory milestone not only clears the clinical...

Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the...

CaaMTech, a drug discovery company in the psychedelics space, has closed a $22 million Series A financing round. The company is focused on building a patent library of analytically pure, well-characterized psychedelic drugs for psychiatry and other health purposes. “We have been screening...

In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.  The industry grew closer to federal legalization of the first psychedelic compounds for therapeutic use. With scientific, regulatory and corporate developments becoming...

Numinus and MAPS Collaborate to Study MDMA in Canada Numinus Wellness (TSXV: NUMI) and the MAPS Public Benefit Corporation have joined forces to bring MDMA-assisted psychotherapy through clinical trials for approval in Canada. The pair will first seek permission to perform a single-arm, open-label...